Clinical Decision Support Tool for Vancomycin Dosing in Children
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 75 people enrolled
- Started
- 9 May 2022
- Ended
- 10 May 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Computer Decision Support Tool Intervention Group
- Matched Historical Controls
- Record updated
- 14 May 2025
Who can take part
- Age
- Up to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Hospitalized infants and children from postmenstrual age of 38 weeks to age 19 years Requiring IV vancomycin, regardless of indication
- Parent or legally authorized representative is willing to provide permission and sign the informed consent document; subjects assent, when appropriate
- Hospitalized neonates, infants, children, adolescents who require, but have not been initiated on intravenous vancomycin therapy
Who cannot take part
- Patients who had received vancomycin during previous 2 weeks
- Patients with end-stage renal disease, receiving hemodialysis or receiving continuous renal replacement therapy
- Receiving extracorporeal therapy, including extracorporeal membrane oxygenation, continuous renal replacement therapy, and extracorporeal liver support
- On oral or intraperitoneal vancomycin
- Will only receive a single dose of vancomycin
- Known to be pregnant
- Is brain dead or has suspected brain death
Where in United States
- University of Maryland Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
This study will evaluate the pharmacokinetic and pharmacodynamic dosing properties of intravenous vancomycin in pediatric patients using a novel computer decision support (CDS) tool called Lyv. Dosing will be individualized based on AUC24/MIC. The results will be compared to matched historical controls.
The 2 groups in the trial
- Intervention Group- Computer Decision Support ToolTreatment being tested
Patients enrolled in the study will be started on IV vancomycin which will be dosed based on the LYV CDS tool, which will dose patients based on AUC24/MIC. Dosing will be adjusted based on vancomycin levels that will be drawn throughout the hospital stay. All patients prospectively enrolled into this study will be in the intervention group. Results will be compared to the retrospectively matched historical controls.
Treatment: Computer Decision Support Tool Intervention Group
- Matched Historical ControlsOther group
Match historical controls are patients that were on IV vancomycin with dose adjustments based on vancomycin trough levels. Patients in this study arm will be retrospective patients that will be matched with the intervention group.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pharmacokinetic Study to Evaluate the Use of a Novel Clinical Decision Support Tool, Lyv, in Achieving AUC24/MIC > 400 in Pediatric Patients on Vancomycin
- Record updated
- 14 May 2025